Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

Brisbois, Tristin Dawne; Kock, Ingrid Heila de; Watanabe, Sharon; Mirhosseini, Mehrnoush; Lamoureux, D.C.; Chasen, Martin; MacDonald, Neil; Baracos, Vickie E.; Wismer, Wendy V.

doi:10.1093/annonc/mdq727

Cited by 192 publications

(221 citation statements)

References 39 publications

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…Of the 12 included studies, six tested supportive TSA interventions [9][10][11][12][13][14], four tested interventions to prevent TSA [15][16][17][18] and two tested both supportive and preventive interventions [19,20]. The primary end point of 11 studies was the effects of the intervention on TSA.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients

Thorne

Olson

Wismer

2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…This was a proof-of-principle study and was intended to provide direction for future trials [9]. Adult patients with advanced cancer experiencing TSA were given marinol (delta-9-tetrahydrocannabinol (THC) 2.5 mg) or a placebo twice daily, to determine its effect on TSA.…”

Section: Marinolmentioning

confidence: 99%

A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients

Thorne

Olson

Wismer

2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Compared with placebo, patients receiving dronabinol reported improved taste (55% vs 10%), increased appreciation of food (73% vs 30%), and a statistically significant increase in appetite. 240 …”

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

395

351

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

“…A small Canadian study using oral dronabinol in advanced cancer patients demonstrated improved sense of taste and subsequent increased protein consumption. That change did not translate to weight gain, but patients did express improvement in quality of life measurements 55 .…”

Section: Appetite Stimulationmentioning

confidence: 96%

A User’s Guide to Cannabinoid Therapies in Oncology

Maida

Daeninck

2016

Current Oncology

View full text Add to dashboard Cite

ABSTRACT"Cannabinoid" is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors.Patients with malignant disease represent a cohort within health care that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options. Cannabinoid therapies are varied and versatile, and can be offered as pharmaceuticals (nabilone, dronabinol, and nabiximols), dried botanical material, and edible organic oils infused with cannabis extracts. Cannabinoid therapy regimens can be creative, involving combinations of all of the aforementioned modalities. Patients with malignant disease, at all points of their disease trajectory, could be candidates for cannabinoid therapies whether as monotherapies or as adjuvants.The most studied and established roles for cannabinoid therapies include pain, chemotherapy-induced nausea and vomiting, and anorexia. Moreover, given their breadth of activity, cannabinoids could be used to concurrently optimize the management of multiple symptoms, thereby reducing overall polypharmacy. The use of cannabinoid therapies could be effective in improving quality of life and possibly modifying malignancy by virtue of direct effects and in improving compliance or adherence with disease-modulating treatments such as chemotherapy and radiation therapy.

show abstract

Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

Abstract: THC may be useful in the palliation of chemosensory alterations and to improve food enjoyment for cancer patients.

Cited by 192 publications

References 39 publications

A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients

A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients

Oral complications of cancer and cancer therapy

A User’s Guide to Cannabinoid Therapies in Oncology

Contact Info

Product

Resources

About